Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Health Canada's approval is based on data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults aged 60 years and older in 22 countries. No serious safety ...

Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of ...

Ladapo opposed mandatory closings and mask mandates for Florida schools while publishing data showing that the ... negative] ...